Yale researchers have identified that the acute inflammatory response to biomaterials can be limited by inhibition of inflammasome-related pathways.
Mice that overexpress TGF-β have identified several novel targets (including β1 integrin) for therapeutic interventions in fibrotic lung diseases. Semaphorin 7A inhibition is also effective as a therapeutic treatment for fibrotic disease.
Yale researchers created an inactivated version of the thyphoid toxin, which can serve as the basis for the development of novel second-generation vaccines to treat typhoid fever.
OCR 5339 is a novel serum-based biomarker assay that determines disease severity and provides a prediction of the progression of scleroderma.
GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.
Dr. Arnsten has discovered in animal studies that exposure to uncontrollable stress impairs prefrontal cortical function via activation of protein kinase C, and that administration of chelerythrine or a chelerythrine analog in accordance with the invention inhibits harmful protein kinase C activation.